{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:05:22Z","timestamp":1789247122064,"version":"build-2803163510"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 24% of new cases of B-cell non-Hodgkin lymphoma in the US each year. Up to 50% of patients relapse or are refractory (R\/R) to the standard first-line treatment option, R-CHOP. The anti-CD19 monoclonal antibody tafasitamab, in combination with lenalidomide (LEN), is an NCCN preferred regimen for transplant-ineligible patients with R\/R DLBCL and received accelerated approval in the US (July 2020) and conditional marketing authorization in Europe (August 2021) and other countries, based on data from the L-MIND study. The recommended dose of tafasitamab is 12 mg\/kg by intravenous infusion, administered in combination with LEN 25 mg for 12 cycles, followed by tafasitamab monotherapy until disease progression or unacceptable toxicity. Tafasitamab + LEN is associated with durable responses in patients with R\/R DLBCL. The majority of clinically significant treatment-associated adverse events are attributable to LEN and can be managed with dose modification and supportive therapy. We provide guidelines for the management of patients with R\/R DLBCL treated with tafasitamab and LEN in routine clinical practice, including elderly patients and those with renal and hepatic impairment, and advice regarding patient education as part of a comprehensive patient engagement plan. Our recommendations include LEN administration at a reduced dose if required in patients unable to tolerate the recommended dose. No dose modification is required for tafasitamab in special patient populations.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac256","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T05:51:19Z","timestamp":1669355479000},"page":"199-207","source":"Crossref","is-referenced-by-count":14,"title":["Clinical Treatment Guidelines for Tafasitamab plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma"],"prefix":"10.1093","volume":"28","author":[{"given":"Adrienne","family":"Nedved","sequence":"first","affiliation":[{"name":"Department of Pharmacy , Mayo Clinic, Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kami","family":"Maddocks","sequence":"additional","affiliation":[{"name":"Arthur G. James Comprehensive Cancer Center, Ohio State University Wexner Medical Center , Columbus, OH , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz S","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Mayo Clinic, Rochester, MN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,17]]},"reference":[{"issue":"5","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol."},{"key":"2023041012083271900_","doi-asserted-by":"crossref","DOI":"10.32388\/5OWTL5","article-title":"Surveillance, Epidemiology, and End Results Program.","volume-title":"Cancer Stat Facts: NHL \u2014 Diffuse Large B-Cell Lymphoma (DLBCL)","author":"National Cancer Institute."},{"key":"2023041012083271900_","volume-title":"NCCN Guidelines: B-Cell Lymphomas v3.2022","author":"National Comprehensive Cancer Network."},{"issue":"22","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21228553","article-title":"Novel therapies for relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Harris","year":"2020","journal-title":"Int J Mol Sci ."},{"issue":"5","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.4049\/jimmunol.1201000","article-title":"A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice","volume":"189","author":"Poe","year":"2012","journal-title":"J Immunol."},{"issue":"19","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Cancer Res."},{"issue":"6","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood-2009-06-229039","article-title":"CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody","volume":"115","author":"Awan","year":"2010","journal-title":"Blood."},{"issue":"25","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","article-title":"Mechanisms of action of lenalidomide in B-cell non-hodgkin lymphoma","volume":"33","author":"Gribben","year":"2015","journal-title":"J Clin Oncol."},{"issue":"7","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"MONJUVI.","year":"2020"},{"key":"2023041012083271900_","volume-title":"Minjuvi","author":"European Medicines Agency."},{"key":"2023041012083271900_","volume-title":"Drug Product Database: Minjuivi","author":"Government of Canada, Health Canada, Public Affairs C and RB.","year":"2021"},{"key":"2023041012083271900_","volume-title":"MinjuviTM, Pulver f\u00fcr ein Konzentrat zur Herstellung einer Infusionsl\u00f6sung (Tafasitamabum) [Minjuvi authorisation]","author":"SwissMedic.","year":"2022"},{"issue":"9","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3324\/haematol.2020.275958","article-title":"Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"106","author":"Duell","year":"2021","journal-title":"Haematologica."},{"issue":"5","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin\u2019s lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol."},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"REVLIMID (lenalidomide).","year":"2019"},{"key":"2023041012083271900_","volume-title":"Summary of Product Characteristics","author":"REVLIMID (lenalidomide).","year":"2021"},{"issue":"12","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol."},{"issue":"12","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol."},{"issue":"10","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1124\/dmd.119.086488","article-title":"Mechanisms influencing the pharmacokinetics and disposition of monoclonal antibodies and peptides","volume":"47","author":"Datta-Mannan","year":"2019","journal-title":"Drug Metab Dispos."},{"issue":"19","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"New Engl J Med."},{"issue":"2","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2011.165","article-title":"Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study","volume":"25","author":"Nowakowski","year":"2011","journal-title":"Leukemia."},{"issue":"22","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol."},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"NEUPOGEN (filgrastim).","year":"2021"},{"issue":"8","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood."},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"YESCARTA (axicabtagene ciloleucel).","year":"2017"},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"KYMRIAH (tisagenlecleucel).","year":"2017"},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"BREYANZI (lisocabtagene maraleucel).","year":"2021"},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"XPOVIO (selinexor).","year":"2019"},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"POLIVY (polatuzumab vedotin-piiq).","year":"2019"},{"key":"2023041012083271900_","volume-title":"Prescribing Information","author":"ZYNLONTA (loncastuximab tesirine-lpyl).","year":"2021"},{"issue":"2","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/pharmaceutics12020194","article-title":"Chimeric antigen receptor-T-cell therapy for B-cell hematological malignancies: an update of the pivotal clinical trial data","volume":"12","author":"Roex","year":"2020","journal-title":"Pharmaceutics."},{"issue":"7","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1080\/0284186X.2020.1741680","article-title":"Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas","volume":"59","author":"El-Galaly","year":"2020","journal-title":"Acta Oncol (Madr)."},{"issue":"4","key":"2023041012083271900_","first-page":"1","article-title":"Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: a meta-analysis","volume":"13","author":"Al-Mansour","year":"2020","journal-title":"Mol Clin Oncol."},{"issue":"13","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/10428194.2021.1992622","article-title":"CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas","volume":"63","author":"Fitzgerald","year":"2022","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1080\/10428194.2021.1986219","article-title":"CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study","volume":"63","author":"Duell","year":"2022","journal-title":"Leuk Lymphoma."},{"key":"2023041012083271900_","first-page":"100260","article-title":"Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody tafasitamab in relapsed\/refractory DLBCL","volume":"16","author":"Tabbara","year":"2021","journal-title":"Leuk Res Rep."},{"issue":"16","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"2023041012083271900_","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1007\/s13187-018-1406-9","article-title":"Optimizing patient education of oncology medications: a patient perspective","volume":"34","author":"Lambourne","year":"2019","journal-title":"J Cancer Educ."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/199\/49806734\/oyac256.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/3\/199\/49806734\/oyac256.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T15:02:07Z","timestamp":1701442927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/3\/199\/6989635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,17]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,1,17]]},"published-print":{"date-parts":[[2023,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac256","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2023,1,17]]}}}